EUVIMEDOpdag EUVIMED
KommentarKohortenstudieOpen access · CC BY-NC 4.0

Neurological phenotype of adenosine deaminase 2 deficient patients: a cohort study

Merelijne A Verschoof iD, Laura C C van Meenen iD, M Valérie E Andriessen, Daniëlle M C Brinkman, Sylvia Kamphuis, Taco W Kuijpers, Helen L Leavis, G Elizabeth Legger, Catharina M Mulders-Manders, Anne P J de Pagter, Abraham Rutgers, Gijs T J van Well and 4 more

European Journal of Neurology · 2024

DOI: 10.1111/ene.16043 ↗

At a glance

Kommentar in European Journal of Neurology, 2024. Written by Merelijne A Verschoof and 15 co-authors. Institution: Department of Neurology, HagaZiekenhuis, The Hague, The Netherlands. Major MEDLINE topics: Ischemic Stroke, Brain Ischemia, Stroke, Ischemic Attack, Transient. Cited 5 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and purpose Patients with adenosine deaminase 2 (ADA2) deficiency can present with various neurological manifestations due to vasculopathies and autoinflammation. These include ischaemic and hemorrhagic stroke, but less clearly defined neurological symptoms have also been reported.

Methods

In this cohort study, patients with confirmed ADA2 deficiency from seven university hospitals in the Netherlands were included. The frequency and recurrence rates of neurological manifestations before and after initiation of tumor necrosis factor α (TNF‐α) inhibiting therapy were analyzed.

Results

Twenty‐nine patients were included with a median age at presentation of 5 years (interquartile range 1–17). Neurological manifestations occurred in 19/29 (66%) patients and were the presenting symptom in 9/29 (31%) patients. Transient ischaemic attack (TIA)/ischaemic stroke occurred in 12/29 (41%) patients and was the presenting symptom in 8/29 (28%) patients. In total, 25 TIAs/ischaemic strokes occurred in 12 patients, one after initiation of TNF‐α inhibiting therapy and one whilst switching between TNF‐α inhibitors. None was large‐vessel occlusion stroke. Two hemorrhagic strokes occurred: one aneurysmatic subarachnoid hemorrhage and one spontaneous intracerebral hemorrhage. Most neurological symptoms, including cranial nerve deficits, vertigo, ataxia and seizures, were caused by TIAs/ischaemic strokes and seldom recurred after initiation of TNF‐α inhibiting therapy.

Conclusions

Neurological manifestations, especially TIA/ischaemic stroke, are common in patients with ADA2 deficiency and frequently are the presenting symptom. Because it is a treatable cause of young stroke, for which antiplatelet and anticoagulant therapy are considered contraindicated, awareness amongst neurologists and pediatricians is important. Screening for ADA2 deficiency in young patients with small‐vessel ischaemic stroke without an identified cause should be considered.

Subjects

MeSH terms (MEDLINE)

Ischemic StrokeBrain IschemiaStrokeIschemic Attack, TransientCohort StudiesSevere Combined ImmunodeficiencyChild, PreschoolPhenotypeHumansIntercellular Signaling Peptides and ProteinsAgammaglobulinemiaAdenosine DeaminaseTumor Necrosis Factor-alpha

Author keywords

ADA2 deficiencypediatric strokeyoung stroke

Substances

ADA2 protein, humanAdenosine DeaminaseIntercellular Signaling Peptides and ProteinsTumor Necrosis Factor-alpha

Authors and institutions

  • Department of Neurology, HagaZiekenhuis, The Hague, The Netherlands.
  • Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Department of Pediatrics, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Pediatric Rheumatology, Sophia Children's Hospital, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Pediatric Immunology and Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

ORCID profiles: Merelijne A Verschoof, Laura C C van Meenen, Femke C C Klouwer

Cite

APA

Verschoof, M. A., van Meenen, L. C. C., Andriessen, M. V. E., Brinkman, D. M. C., Kamphuis, S., Kuijpers, T. W., Leavis, H. L., Legger, G. E., Mulders-Manders, C. M., de Pagter, A. P. J., Rutgers, A., van Well, G. T. J., Coutinho, J. M., Hak, A. E., van Montfrans, J. M., & Klouwer, F. C. C. (2024). Neurological phenotype of adenosine deaminase 2 deficient patients: a cohort study. European Journal of Neurology. https://doi.org/10.1111/ene.16043

Vancouver

Verschoof MA, van Meenen LCC, Andriessen MVE, Brinkman DMC, Kamphuis S, Kuijpers TW, et al. Neurological phenotype of adenosine deaminase 2 deficient patients: a cohort study. European Journal of Neurology. 2024. doi:10.1111/ene.16043

BibTeX
@article{Verschoof2024,
  author = {Verschoof, Merelijne A and van Meenen, Laura C C and Andriessen, M Valérie E and Brinkman, Daniëlle M C and Kamphuis, Sylvia and Kuijpers, Taco W and Leavis, Helen L and Legger, G Elizabeth and Mulders-Manders, Catharina M and de Pagter, Anne P J and Rutgers, Abraham and van Well, Gijs T J and Coutinho, Jonathan M and Hak, A Elisabeth and van Montfrans, Joris M and Klouwer, Femke C C},
  title = {Neurological phenotype of adenosine deaminase 2 deficient patients: a cohort study},
  journal = {European Journal of Neurology},
  year = {2024},
  doi = {10.1111/ene.16043}
}
Start for free →